$CUE Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of -$24.14 down -804.12% YoY
• Reported revenue of $7.88M up 166.66% YoY
• Cue Biopharma, Inc. believes that its cash and cash equivalents on hand as of June 30, 2026, along with the net proceeds from the July 2026 private placement, will be sufficient.